Cellectis (CLLS) Interest & Investment Income (2022 - 2026)
Cellectis (CLLS) posted quarterly Interest & Investment Income of $11.9 million for Q1 2026, up 88.84% year-over-year from $6.3 million in Q1 2025, and up 489.93% quarter-over-quarter from $2.0 million in Q4 2025.
Cellectis (CLLS) Interest & Investment Income (2022 - 2026) Analysis & Trends
Cellectis' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $11.9 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 88.84% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $22.9 million (down 29.36% YoY), while the FY2025 annual figure was $16.1 million, down 63.69% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $11.9 million, up from $2.0 million in the prior quarter.
- The five-year high for Interest & Investment Income was $29.4 million in Q1 2024, with the low at -$6.3 million in Q4 2022.
- The 5-year median for Interest & Investment Income is $5.3 million (2023), against an average of $6.8 million.
- The sharpest annual moves came in 2024 and 2025: Interest & Investment Income jumped 3694.84% in 2024, then plunged 86.27% in 2025.
- Cellectis' Interest & Investment Income stood at -$6.3 million in 2022, then jumped by 185.15% to $5.3 million in 2023, then surged by 174.6% to $14.7 million in 2024, then slumped by 86.27% to $2.0 million in 2025, then jumped by 489.93% to $11.9 million in 2026.
- Business Quant data shows CLLS's Interest & Investment Income at $11.9 million in Q1 2026, $2.0 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 11.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.89 Mn |
| Dec 31, 2025 | 2.02 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 6.30 Mn |
| Dec 31, 2024 | 14.68 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | 8.40 Mn |
| Mar 31, 2024 | 29.41 Mn |
| Dec 31, 2023 | 5.35 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Jun 30, 2023 | 10.44 Mn |
| Mar 31, 2023 | 775,000.00 |
| Dec 31, 2022 | -6.28 Mn |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 9.99 Mn |
| Mar 31, 2022 | 2.27 Mn |